Narcotic Antagonists and Strategies for Enhancing Their Effectiveness

  • Albert A. Kurland


A series of clinical trials employing the narcotic antagonist, naloxone, administered on a maintenance and on a contingent basis, have indicated that the therapeutic promise of these compounds has not been borne out. Similar investigative experiences appear to be in the process of being reduplicated by the more potent narcotic antagonist naltrexone. These have emphasized the need for treatment approaches which might enhance the patient’s motivation relative to the treatment endeavor. One such possiblity is the structuring of a dramatic treatment experience prior to the initiation of treatment with a narcotic antagonist. For this purpose the use of psychedelic psychotherapy is suggested.


Antagonist Treatment Opioid User Abstinence Syndrome Opiate Dependence Heroin Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Blumberg, H., Dayton, H.B., George, M. and Rapaport, D.N. 1961. N-allylnoroxymorphine: a potent narcotic antagonist. Fed. Proc. 20: 311.Google Scholar
  2. Blumberg, H. and Dayton, H.B. 1972. Narcotic antagonist studies with EN-161639A (N-cyclopropylmethylnoroxymorphone). In: Fifth International Congress on Pharmacology, San Francisco. Abstracts of volunteer papers.Google Scholar
  3. Fink, M. 1970. Narcotic antagonists in opiate dependence. Science 169: 1005–1006.CrossRefGoogle Scholar
  4. Hanlon, T.E. et al. 1977. Narcotic antagonist treatment of addict parolees-the future of an effective approach. Comp. Psych. 18: 211–219.CrossRefGoogle Scholar
  5. Kurland, A.A. 1978. Psychiatric Aspects of Drug Dependence. West Palm Beach, Florida. CRC Press, Inc.Google Scholar
  6. Martin, W.F., Gorodetzky, C.W., and McClane, T.K. 1966. An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. Ther. 7: 455–465.Google Scholar
  7. Martin, W.R., Jasinski, F.P. and Mansky, P.A. 1973. Naltrexone, an antagonist for the treatment of heroin dependence: effects in man. Arch. Gen. Psych. 28: 784–791.CrossRefGoogle Scholar
  8. Report of the National Research Council Committee on Clinical Eval-uation of Narcotic Antagonists, 1978. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Arch. Gen. Psych. 35: 335–340.Google Scholar
  9. Wikler, A. 1974. Opioid Antagonists and Deconditioning in Addiction Treatment. Paper presented at the syposium on drug dependence-treatment and treatment evaluation. Spandia Interna. Symposium. Stockholm, Sweeden.Google Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • Albert A. Kurland
    • 1
  1. 1.Maryland Psychiatric Research CenterUSA

Personalised recommendations